Elucid welcomed Amy Kruglak for four years.
Published
Signal category
People
Quote
“Four years at Elucid!”
— Amy Kruglak, SPHR|Elucid team
Company
Elucid
Predicting and personalizing the prevention of heart attacks & strokes
- Industry
- Medical Equipment Manufacturing
- Location
- Boston, US
- Company size
- 146 employees
Elucid is a Boston-based AI medical technology company that develops AI to see invisible features of risk. The company is dedicated to developing a clinical platform to help physicians deliver CCTA-guided personalized care by providing a more precise view of atherosclerosis, the root cause of cardiovascular disease. The company’s FDA-cleared Plaque-IQ™ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR-CT, derived from its plaque algorithm, resulting in concordance between plaque and FFR-CT. FFR-CT helps physicians identify coronary blockages and the extent of a patient’s ischemia non-invasively. For more information, visit elucid.com.
Founded 2013